The ADVANCING ACCESS® patient assistance program is committed to helping patients afford their Gilead medication, including:

  • Atripla® (efavirenz/emtricitabine/tenofovir disoproxil fumarate); Complera® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate); Descovy® (emtricitabine/tenofovir alafenamide ); Emtriva® (emtricitabine); Genvoya® (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide); Odefsey® (emtricitabine/rilpivirine/tenofovir alafenamide ); Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate); Truvada® (emtricitabine/tenofovir disoproxil fumarate); Tybost® (cobicistat); Vitekta® (elvitegravir); Viread® (tenofovir disoproxil fumarate)

Advancing Access provides assistance to patients who are uninsured, underinsured or who need financial assistance to pay for the medicine. The program offerings for patients include:

  • Access to call center associates who can help patients and their providers with insurance-related questions, including providing information regarding coverage options.
  • Provides co-pay assistance for eligible patients who need assistance paying for out-of-pocket medication costs.
  • The Advancing Access patient assistance program provides Gilead medications at no charge for eligible patients with no other insurance options. Not valid for patients enrolled in government healthcare prescription drug programs, such as Medicare Part D and Medicaid. Patients in the coverage gap known as the "donut hole" also are not eligible.

Information about how to apply for any of these forms of assistance can be found at or by calling 1-800-226-2056 between 9:00 a.m. and 8:00 p.m. (Eastern).